Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company that develops oral, small-molecule therapies for severe muscle diseases. Its pipeline targets muscular dystrophies and cardiac conditions. The lead candidates are sevasemten (EDG-5506) for Becker and Duchenne muscular dystrophy, and EDG-7500 for hypertrophic cardiomyopathy. The company's mission is to improve the lives of patients with rare muscle disorders.